Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

TriSalus Life Sciences Inc.

Healthcare US TLSI

3.17USD
-0.13(3.94%)

Last update at 2026-06-05T20:00:00Z

Day Range

3.163.33
LowHigh

52 Week Range

3.3212.83
LowHigh

Fundamentals

  • Previous Close 3.30
  • Market Cap214.56M
  • Volume304079
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-53.44800M
  • Revenue TTM18.51M
  • Revenue Per Share TTM1.97
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.6

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31
Type yearly yearly
Date 2022-12-31 2021-12-31
Income before tax -47.17800M -28.84200M
Minority interest - -
Net income -47.18700M -28.84500M
Selling general administrative 12.48M 8.75M
Selling and marketing expenses 12.74M 8.26M
Gross profit 10.14M 7.21M
Reconciled depreciation 0.40M 0.46M
Ebit -44.99100M -23.28600M
Ebitda -44.59300M -22.82200M
Depreciation and amortization 0.40M 0.46M
Non operating income net other - -
Operating income -36.43900M -24.03200M
Other operating expenses 48.84M 32.43M
Interest expense 0.00100M 1.76M
Tax provision 0.00900M 0.00300M
Interest income 0.18M 0.00000M
Net interest income 0.18M -1.76100M
Extraordinary items - -
Non recurring - -
Other items - -
Income tax expense 0.00900M 0.00300M
Total revenue 12.40M 8.40M
Total operating expenses 46.58M 31.24M
Cost of revenue 2.26M 1.19M
Total other income expense net -10.91800M -3.04900M
Discontinued operations - -
Net income from continuing ops -47.18700M -28.84500M
Net income applicable to common shares - -
Preferred stock and other adjustments - -
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Total assets 25.73M 22.00M 252.01M
Intangible assets 1.13M - -
Earning assets - - -
Other current assets 2.99M 0.21M 0.67M
Total liab 51.66M 198.32M 8.85M
Total stockholder equity -25.93800M -176.32900M 243.16M
Deferred long term liab - - -
Other current liab 0.39M 27.04M 0.10M
Common stock 0.00200M 0.01M 238.16M
Capital stock 0.00200M 0.01M 0.01M
Retained earnings -248.37700M -186.35800M -0.10519M
Other liab - - -
Good will - - -
Other assets - - -
Cash 11.78M 9.41M 1.33M
Cash and equivalents - - -
Total current liabilities 14.69M 32.36M 0.10M
Current deferred revenue 10.56M 6.38M -
Net debt -10.18200M -7.45100M -1.33500M
Short term debt 0.35M 0.37M -
Short long term debt - - -
Short long term debt total 1.59M 1.96M 0.54M
Other stockholder equity 222.44M 10.02M 5.10M
Property plant equipment - - -
Total current assets 20.86M 17.21M 2.01M
Long term investments - - -
Net tangible assets - - -
Short term investments - - -
Net receivables 3.55M 1.56M 1.36M
Long term debt - - -
Inventory 2.54M 1.47M 1.29M
Accounts payable 3.39M 4.95M 1.30M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other 0.47M -19.46088M 250.00M
Deferred long term asset charges - - -
Non current assets total 4.86M 4.78M 250.00M
Capital lease obligations 1.59M 1.96M 0.00000M
Long term debt total - - -
Breakdown 2022-12-31 2021-12-31
Type yearly yearly
Date 2022-12-31 2021-12-31
Investments -1.78600M -2.25800M
Change to liabilities - -
Total cashflows from investing activities - -
Net borrowings - -
Total cash from financing activities 13.46M 50.77M
Change to operating activities - -
Net income -47.18700M -28.84500M
Change in cash -20.63700M 25.81M
Begin period cash flow 30.30M 4.49M
End period cash flow 9.66M 30.30M
Total cash from operating activities -32.31300M -22.69700M
Issuance of capital stock 13.50M 52.02M
Depreciation 0.40M 0.46M
Other cashflows from investing activities - -
Dividends paid - -
Change to inventory -0.17900M -0.72500M
Change to account receivables -0.20000M -0.74100M
Sale purchase of stock - -
Other cashflows from financing activities 13.59M 52.12M
Change to netincome - -
Capital expenditures 0.79M 1.26M
Change receivables - -
Cash flows other operating - -
Exchange rate changes - -
Cash and cash equivalents changes - -
Change in working capital 2.30M -0.13100M
Stock based compensation 0.37M 0.11M
Other non cash items 11.81M 5.71M
Free cash flow -33.09900M -23.95500M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TLSI
TriSalus Life Sciences Inc.		 -0.13 3.94% 3.17 - - 15.33 30.29 16.95 -5.9552
ABT
Abbott Laboratories		 0.29 0.32% 91.07 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 4.45 1.48% 305.66 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.26 0.32% 81.67 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.3 0.61% 48.55 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

TriSalus Life Sciences Inc.

6272 West 91st Avenue, Westminster, CO, United States, 80031

Key Executives

Name Title Year Born
Ms. Mary T. Szela B.S.N., M.B.A. CEO, President & Director 1964
Mr. Sean Edward Murphy CFO & Director 1953
Dr. Steven C. Katz F.A.C.S., M.D. Chief Medical Officer & Chairman of Scientific Advisory Board 1975
Ms. Jennifer L. Stevens J.D. Chief Regulatory Officer 1961
Ms. Lori Ann Santamaria Vice President of Operations NA
Dr. Bryan F. Cox Ph.D. Chief Scientific & Manufacturing Officer 1962
Mr. James E. Young Senior VP of Investor Relations & Treasurer NA
Ms. Rachel Garcia Marketing Manager NA
Dr. Richard B. Marshak M.B.A., MBA, VMD Senior Vice President of Corporate Development & Strategy 1959
Ms. Jodi Devlin President of Commercial Operations 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions